Amphion Innovations PLC Amphion Partner Motif Can Help Solve Health Crisis
08 Julio 2014 - 1:00AM
RNS Non-Regulatory
TIDMAMP
Amphion Innovations PLC
08 July 2014
Amphion Innovations plc
("Amphion")
Amphion Partner, Motif, Poised to Help Solve Global Health
Crisis
London and New York, 8 July 2014: Amphion Innovations plc (LSE:
AMP), the developer of medical and technology businesses, notes
Prime Minister David Cameron's 2 July 2014 statement pertaining to
the launch of a new global taskforce, established to coordinate an
international effort to combat antibiotic resistant superbugs. The
taskforce, which is to be chaired by economist Jim O'Neill, will
focus on how to find and develop new drugs, specifically
antibiotics, in order to combat the ever-growing and serious
problem of these antibiotic resistant superbugs.
Prime Minister David Cameron commented: "Resistance to
antibiotics is now a very real and worrying threat as bacteria
mutate to become immune to their effects. With some 25,000 people a
year already dying of infections resistant to antibiotic drugs in
Europe alone, this is not some distant threat but something
happening right now. If we fail to act, we are looking at an almost
unthinkable scenario where antibiotics no longer work and we are
cast back to the dark ages of medicine where treatable infections
and injuries can kill once again" - Source: 2 July 2014 Wellcome
Trust Press Release
Amphion's Partner Company, Motif BioSciences Ltd. ("Motif"), a
cutting-edge drug discovery/development company based in New York
City, has a stated mission to develop solutions addressing the
antibiotic crisis. Motif is currently developing two new
antibiotics that work in different ways to those commonly used
today. In the opinion of the management team, no other
companyworldwide is currently developing antibiotics with the same
mechanism. The highly experienced scientific team at Motif believes
that these two new antibiotics will be particularly well equipped
for commercial success. Motif's target is to have two new
antibiotics ready to launch to the healthcare market and the
management team looks forward to providing an update on details and
timing in due course.
Amphion's Chief Executive Officer and Chairman of Motif, Richard
Morgan, said: "We welcome the recent remarks made by Prime Minister
Cameron regarding the antibiotic crisis and the initiatives he
announced. With its leading team of experts, strategic
partnerships, and new antibiotic candidates, Motif is poised to
help address this situation.
"Amphion is currently the largest outside shareholder in Motif,
which is second in size and importance in terms of our investment
holdings. We look forward to seeing the company progress its
development programmes and believe the upside potential to be very
large if the company is successful."
For further information please contact:
Amphion Innovations
Charlie Morgan +1 212 210 6224
Novella Communications
Tim Robertson / Ben Heath +44 020 3151 7008
Panmure Gordon Limited
Freddy Crossley / Fred Walsh (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking) +44 020 7886 2500
About Amphion Innovations plc:
Amphion (LSE: AMP) builds shareholder value in emerging
companies in the medical and technology sectors, by using a
focused, hands-on company building approach, based on decades of
experience in both the US and UK. Amphion has significant
shareholding in 7 Partner Companies developing proven technologies
targeting substantial commercial marketplaces. The Amphion model
has been refined to optimise the commercialisation of patents and
other intellectual property within the Partner Companies. The
Partner Companies collectively own or control over 200 separately
identified pieces of intellectual property, a number which grows
rapidly each year.
On the web: www.amphionplc.com and www.motifbio.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAPXXEEALEFF
Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024